Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

Sanofi said that Sarclisa, its treatment for plasma cell cancer, was recommended for EU approval by the European Medicines Agency. The agency's Committee for Medicinal Products for Human Use ...

A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication that the market for GLP-1 drugs could likely be a lot bigger. Based on data ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.

In 2015, researchers discovered that some species, like Conus geographus, make venoms that contain con-insulin, a toxin that ...

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare disease targets.

Insulin production is dominated by the US’s Eli Lilly and Europe’s Sanofi and Novo Nordisk ... but growing over time.” New ...